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Abstract 
Mechanical circulatory support is the most rapidly evolving strategy in heart 
failure management. The growing number of patients who need better results 
than medical therapy can offer, the limited pool of donors for cardiac 
transplantation, and several technological breakthroughs have all made the 
option of implanting a left ventricular assist device (LVAD) as destination therapy 
more important.  
In this review, we outline the indications and decision making process of 
considering a patient for a destination therapy LVAD, as well as outcomes, 
complications, and issues related to management of patients on currently 
approved devices. The future direction of the field will be determined by progress 
in technology and by further improvement in size, durability, pump dynamics, and 
most importantly, by solving the problem of supplying energy to the pump without 
a percutaneous driveline.   
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End Destination of Heart Failure Is LVAD 
The population of patients with heart failure (HF) is growing at a rate approaching 
that of an epidemic. This means that although only a small fraction of patients 
with heart failure progress to the end-stages of the disease, there are probably 
between 100,000 and 250,000 patients in the United States who have exhausted 
traditional methods of treatment, including all evidence-based medications and 
pacemaker-based therapies (1). 
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Meanwhile, the number of heart transplants in the United States has remained at 
about 2,500 per year for several decades (2). Unless we learn how to make 
better artificial hearts, or learn how to patch failing ventricles using stem cells, the 
vast majority of advanced HF patients will have to be considered as potential 
candidates for mechanical circulatory support. At first, LVADs were thought of as 
a temporary intermediate step that can bridge patients to heart transplantation. 
However, LVADs have now been used as destination therapy (DT) for more than 
a decade and are quickly replacing transplants as the standard therapy. 
This transition was made possible by technological breakthroughs including: 
(a) conversion from external to internal placement of the devices; (b) conversion 
from pneumatic to electrical power; and (c) transition from pulsatile to 
continuous-flow devices. The new continuous-flow LVADs that are currently used 
for DT are much smaller in size and weight and quieter in operation than the first 
pulsatile models. These characteristics improve patient satisfaction and allow the 
technology to support a greater variety of patients. 
According to the sixth Interagency Registry for Mechanically Assisted Circulatory 
Support (INTERMACS) annual report, more than a thousand LVADs were 
implanted for DT indication in 2013(3). This represents a doubling in volume 
since 2010 (Figure 1). This review builds on this clinical progress and discusses 
the most important aspects of LVADs as DT. 
 
Fig 1. Primary adult implants for destination therapy in the INTERMACS 
registry by year of implant (Kirklin et al. (3), with permission). 
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Brief History 
In 2001, the REMATCH (Randomized Evaluation of Mechanical Assistance for 
the Treatment of Congestive Heart Failure) trial demonstrated for the first time 
that mechanical circulatory support as DT for advanced HF is superior to optimal 
medical management (4). This trial was performed using a pulsatile HeartMate I 
(HMI) (Thoratec Corporation, Pleasanton, California) device. This was later 
approved by the Food and Drug Administration (FDA) for DT and subsequently 
covered by Medicare in 2003. 
Later, a continuous flow HeartMate II (HMII) (Thoratec) was proven to provide 
better survival, quality of life, and fewer adverse events, under conditions that 
included use as a DT (5, 6). Since the rotor is the pump’s only moving part, the 
HeartMate II device is very durable with an estimated working life of 5 to 10 
years. The pumps also have good hemocompatibility (that is, they do not cause 
adverse reactions with flowing blood) and can drive adequate cardiac output 
without inducing turbulence, stasis, or clinically significant hemolysis. 
The FDA approved the HeartMate II LVAD for DT in January 2010. Currently, 
over 98% of all LVADs implanted in the United States are continuous flow 
devices (7), and the HMII has proven to be the “work horse” of LVAD centers 
across the United States. At present, it is essentially the only realistic option for 
large-scale implementation of LVAD DT. Heartware (Heartware, Framingham, 
MA), another durable pump with good outcome data, is not yet approved for DT. 
Indications 
According to the most recent guidelines of the American College of Cardiology 
Foundation/American Heart Association (8), VADs are indicated for patients who 
have advanced systolic HF with a left ventricular ejection fraction (LVEF) less 
than 25% and who are in New York Heart Association (NYHA) class III-IV 
functional status. Patients must also have received guideline-directed medical 
therapy including (when indicated) cardiac resynchronization therapy and have a 
high predicted 1- to 2-year mortality (e.g., as suggested by markedly reduced 
peak oxygen consumption or clinical prognostic scores) or be dependent on 
continuous parenteral inotropic support. 
The dependence on continuous intravenous inotropes can be shown for patients 
with low cardiac output by demonstrating that cardiac index improves by at least 
20% after initiation of inotropes (9). Alternatively, patients exhibiting pulmonary 
congestion should show a ≥20% drop in pulmonary capillary wedge pressure 
after inotropes (9). Patients should also fail weaning attempts implemented by an 
experienced HF team. 
In essence, LVAD as DT should be considered for patients who have advanced 
systolic HF and who are (a) otherwise functional, (b) ineligible for cardiac 
transplantation, and (c) have low-output syndrome and/or severe congestion. 
This means that all patients referred for mechanical circulatory support should 
already have had their transplant candidacy assessed (10). Of course, these 
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plans also assume that any potentially reversible causes of systolic HF, such as 
severe aortic stenosis, persistent tachyarrhythmias, ongoing ischemia, etc. have 
been corrected. 
Candidate Selection: LVAD, Transplant, or Hospice?    
The steps for choosing treatments for patients who have advanced HF include: 
• Evaluation for reversible causes of cardiomyopathy/HF. 
• Evaluation for heart transplant eligibility. 
• In patients who are ineligible for heart transplant, evaluation for 
mechanical circulatory support (Figure 1). 
Many conditions that prevent a patient from being candidate for heart 
transplantation do not impact the option of LVAD DT. 
• Age. Age remains the most common reason that patients are 
ruled ineligible for transplant. Many programs consider patients 
aged 70 and over too old to transplant. Meanwhile, patients who 
are at least 70 years of age when they receive an LVAD typically 
perform well with one month, one year, -and two-year survival 
rates, as well as length of stay, not markedly different from data 
obtained from younger patients (11-13). Thus, age alone should 
not be viewed as a contraindication for LVAD.  
• Frailty. One area that is becoming an increasingly important part 
of a DT evaluation is the assessment of frailty. Frailty is a 
biological syndrome that reflects a state of decreased physiologic 
reserve, and can be diagnosed if three or more of the following 
criteria are present: unintentional weight loss (10 pounds in the 
past year), self-reported exhaustion, weakness (typically 
measured as grip strength), slow gait, and low physical activity. 
Post-operative complications are adversely affected by frailty (14) 
and handgrip has been shown to be a particularly effective 
predictor of survival (15). 
• Obesity. Traditionally, transplantation centers establish an 
arbitrary threshold for body mass index (BMI) which they use as a 
criteria for patient selection. This contrasts with data from LVAD 
procedures (16) which show that extremes of body mass index 
are not associated with poor survival in either univariate analysis, 
or in adjusted models (extremely obese: hazard ratio (HR) 1.29, p 
= 0.2; obese: HR 0.94, p = 0.7; underweight: HR 1.23, p = 0.4). 
Extremely obese patients did however have higher rates of 
device-related infection and re-hospitalization (16). Butler et 
al.(17) also reported good outcomes on LVADs in patients with 
high BMI, with similar rates of infectious, neurological, respiratory, 
and bleeding complications as their leaner counterparts, but with 
 	  
	  
	  
The VAD Journal: http://dx.doi.org/10.13023/VAD.2014.02   Page 5 of 39 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
higher re-operation rates and more renal complications. Patients 
with lowest BMI (<22.9) had the worst prognosis (Table 1) (17). 
• Pulmonary hypertension. Patients who have severe fixed 
pulmonary hypertension (defined as pulmonary arterial systolic 
pressure greater than 60 mm Hg, transpulmonary gradient greater 
than 15 mm Hg, or pulmonary vascular resistance greater than 6 
Wood units, while unresponsive to treatment with pulmonary 
vasodilators) are very high risk candidates for cardiac 
transplantation because of the high likelihood of post-operative 
right ventricular failure. These patients can however be treated 
with LVADs which may also reverse the pulmonary hypertension 
by unloading the left ventricle (18, 19). 
• Recent malignancy. By convention, history of malignancy within 
5 years is a contraindication for heart transplant, with rare 
exceptions. However, if the overall prognosis is good from an 
oncologic standpoint, there is no reason not to consider the 
patient for LVAD DT. 
• Human immunodeficiency virus. While the fear of opportunistic 
infections typically precludes these patients from heart transplant, 
they can benefit from LVAD as DT (20). 
• Diabetes. Caution is needed with this condition as outcomes for 
patients with LVADs and diabetes are typically as not as good as 
those for non-diabetics (Odds ratio (OR) 1.76, 95%CI 1.05-2.94) 
(21). Still, patients without severe end-organ damage due to 
diabetes, which would be a contraindication to transplant, can 
benefit from LVAD. Moreover, LVAD implantation with subsequent 
hemodynamic and metabolic optimization can improve the course 
of diabetes mellitus (22-26). 
Congenital heart disease in adults produces more complex physiology than 
simple ischemic or non-ischemic cardiomyopathy. Congenital abnormalities can 
alter the chest anatomy as can prior surgeries performed for palliations and 
surgical repairs. Adhesions, conduits, shunts, patches, and anastomoses create 
multiple surgical challenges. Many centers avoid transplanting these patients 
because their outcomes are frequently worse than those patients who have 
“straightforward” advanced HF. Given the young age of many patients with adult 
congenital heart disease, it is especially important to find options to prolong their 
lives with mechanical circulatory support. The data on LVADs in adult congenital 
cases are limited but promising. A series of 6 cases with systemic right ventricle, 
including 2 patients with single-ventricle physiology, reports 2 deaths and long 
survival on LVADs for the four remaining patients (27). 
Contraindications for LVAD (as well as heart transplantation) include: systemic 
illness with a life expectancy of less than two years, active malignancy with poor 
prognosis, severe aortic disease, severe obstructive pulmonary disease, and 
irreversible renal or hepatic dysfunction. The last condition does however require 
careful consideration as in many cases the dysfunction is secondary to 
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congestion/low output and may therefore be reversible on hemodynamic 
unloading (28, 29). Sometimes a liver biopsy is warranted to differentiate 
cirrhosis from potentially reversible fibrosis. If the team decides that the 
risk/benefit ratio for LVAD is unfavorable, a palliative care consult should be 
obtained to decide on the appropriateness of hospice. The decision making 
process is summarized in Figure 2. 
 
Fig 2. Decision making process on advanced HF management   
Evaluation for LVAD as DT 
The evaluation process is typically performed by a team of specialists that 
includes a HF cardiologist, a cardiothoracic surgeon, a dietitian, a pharmacist, a 
social worker, and a financial consultant. In most programs, the same team 
performs evaluations for heart transplant and LVAD implantation. 
In order to benefit from the LVAD, the patient has to (a) survive the early post-
operative period when most acute complications occur, and (b) maintain good 
functional status for several years in order to maintain a good quality of life after 
the implant. 
To solve the first problem – getting the patient through post-operative period – 
their status has to be optimized before the surgery. This includes: 
• Optimizing hemodynamics with maximal unloading (diuresis with 
or without inotropic support) and treating pulmonary hypertension 
Advanced HF 
LVEF<25%   
NYHA III-IV
Optimal medical management + CRT if indicated
• Six minute walk <300 m 
• Peak VO2<14 mL/kg/min
• Frequent hospital admissions
• Inotrope dependency
• High 1- or 2-year mortality risk by risk score
Eligible for transplant
Heart Transplant 
or LVAD as a bridge
Not eligible for transplant
• Too old
• High BMI
• Pulmonary hypertension
• Recent malignancy   
• HIV
Eligible for LVAD
Heart transplant/LVAD Evaluation
Reversible Cause
YesCorrect the reversible 
cause
No
LVAD
Not Eligible for 
LVAD Hospice
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to decrease pulmonary vascular resistance and prevent post-
operative failure of the right ventricle (RV). 
• Minimizing renal and hepatic insufficiency. 
• Improving nutritional status. 
• Evaluating for potential bleeding and optimizing coagulation 
status. 
• Treating infections and providing antibiotic coverage for 
prophylaxis. 
To prepare the patients for living on LVAD support for a long time, several steps 
are usually undertaken before the decision to operate: 
• Evaluating for serious co-morbidities which may limit longevity 
such as severe chronic obstructive pulmonary disease, severe 
vasculopathy, including atherosclerotic changes in carotis arteries 
or presence of peripheral vascuoar disease, impaired neurologid 
status, or coagulopathy. 
• Evaluating psychological stability, compliance, absence of drug or 
alcohol addiction, social support, and financial reserves. 
Selecting the best candidates for LVAD DT involves optimizing the balance 
between patients who are “too sick” and patients who are “too well”. Extensive 
prognostic data is available from INTERMACS, the unique registry of LVAD 
recipients in the USA which is sponsored by the National Heart, Lung, and Blood 
Institute, the Centers for Medicare and Medicaid Services, FDA, and industry. 
Patients who are entered into the registry are categorized into one of seven 
classes at the time of LVAD implantation. The highest INTERMACS profile 
(profile 1, “crash and burn”) corresponds to cardiogenic shock while profile 7 
equates to stable NYHA III (30). 
Unstable patients in cardiogenic shock (“crash and burn” INTERMACS profile 1) 
have the worst outcomes after they receive an LVAD but also have the most to 
gain if the treatment is successful (31). More stable patients in profiles 3 and 4 
have much better outcomes but their gains in terms of longevity and quality of life 
are moderate. Presumably technical advances will mean that each new 
generation of pump will become better and smaller, and cause less discomfort to 
the patient. This will make LVADs a better option for patients with milder forms of 
HF. The ongoing MEDAMACS study is designed to address this idea and tests 
whether ambulatory patients who are in NYHA III with episodes of 
decompensation can benefit from current LVAD therapy. It’s also pertinent to 
note that some programs implement risk stratification and mortality prediction 
using well validated scores such as the Heart Failure Survival Score (32) and the 
Seattle Heart Failure Model (33). 
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Outcomes 
The field of mechanical circulation has been evolving so rapidly, and 
technological advances have been occurring so frequently, that the data on 
outcomes have been improving continuously. The results of yesterday are no 
longer valid today, and cannot be extrapolated into tomorrow. Outcomes 
obtained with pulsatile pumps are not applicable to continuous flow devices, and 
survival and other important outcomes have improved in each successive trial as 
clinicians gain experience. 
Table 1 shows data on outcomes that we collated from the literature.. Many of 
the results were obtained from studies that included DT and Bridge to Transplant 
(BTT) and from different types of LVAD. Outcomes from trials that studied only 
BTT were not included. Most of the data in Table 1 are survival and length of stay 
values. 
The historic starting point for LVAD DT outcome trials is the REMATCH trial. In 
this work, survival on the pulsatile HMI was 52% at one year and 29% at two 
years which greatly exceeded the survival rates on optimal medical therapy (one 
year, 23%; two year, 8%) (4). Since 2001, the survival of patients receiving 
optimal medical management has very modestly improved but the survival of 
patients receiving LVAD HT has continued to increase. 
Several years later, in the HMII DT trial, patients ineligible for transplantation 
were randomized into continuous flow or pulsatile flow pumps (6). Patients who 
received HMII devices had better 2-year survival free from disabling stroke 
and/or re-operation to repair or replace the device than patients who were 
implanted with the pulsatile pump (46% versus 11%, p<0.001). Patients on HMII 
also had superior actuarial survival rates at 2 years (58% vs. 24%, p=0.008) and 
fewer complications. 
Long term follow-up of HMII patients who were enrolled in the BTT trial showed 
an overall 18-month survival of 72% (5). Interestingly, patients who were enrolled 
later in the trial had better outcomes than patients who were enrolled near the 
beginning (34). The later cohort had better overall survival and fewer 
complications such as bleeding, device-related infections, and hemorrhagic 
stroke. This trend may reflect the growing skill and experience of the LVAD 
teams. 
Heart transplantation is still regarded as the gold standard treatment for 
advanced HF and has an average 2-year survival of approximately 80% (2). 
However survival rates for LVAD DT are now approaching this level. Patients 
who receive a continuous flow LVAD and who do not have risk factors associated 
with high mortality (for example, history of cancer, high blood urea nitrogen, 
and/or cardiogenic shock at implant) have 1 and 2 year survival rates of 88% and 
80% respectively (35). The sixth INTERMACS report shows that actuarial 
survival at 1 and 2 years is 80% and 70% respectively (3). 
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Fig 3. Actuarial survival for continuous flow LVADs (From Kirklin et al. (3), 
with permission) 
Some programs create a so-called “alternative” wait list for patients who have 
advanced age, diabetes, obesity, or renal dysfunction and transplant them with 
sub-optimal hearts that would otherwise be discarded. These hearts typically 
have left ventricular hypertrophy, mild systolic dysfunction, or some coronary 
artery disease. The survival rates for patients who receive these hearts, by a 
single center data, is similar to LVAD DT at one year (82.2% and 77.5%, 
respectively) and better than LVAD DT at three years (73% versus 50%). 
However, when patients who received pulsatile LVADs are excluded from the 
analysis, the outcomes for transplant and LVAD DT are similar at three years as 
well (36). 
Predictably, when patients are unstable at the time of implantation, their 
outcomes are not as good as those of patients who were hemodynamically 
stable. An analysis of three groups of patients with different degrees of HF acuity 
showed that the patients who were most stable (ambulatory HF, INTERMACS 
profiles 4 to 7) had the best survival rate (96%), patients in the intermediate 
group (inotrope-dependent, INTERMACS profiles 2 or 3) had a moderate survival 
rate (69%), and patients in cardiogenic shock (INTERMACS profile 1) had the 
worst outcomes (51% survival) (31). 
Table 1 (see page 10A-10F) shows that two year survival rates for continuous 
flow LVAD DT are generally in the 60~80% range. This is a substantial 
achievement given that the survival rate with optimal medical therapy was only 
8% when the REMATCH trial was performed 15 years ago. Overall quality of life 
with LVAD DT is also good. In patients supported by predominantly HMII devices 
for at least a year, the average six minute walk distance was ~400 m while they 
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mean NYHA class was 1.4 +/- 0.6. These patients did however require about 
three hospital admissions per year and 77% had to undergo additional operations 
(37). 
Myocardial Recovery 
Although it is not common, myocardial recovery is a highly desirable outcome of 
LVAD implementation. Replacing a failing heart with a mechanical pump 
produces multiple beneficial effects. For example, LVAD implantation decreases 
left ventricular dimensions, increases left ventricular ejection, and induces 
regression of cardiomyocyte hypertrophy (41). Hemodynamically, LVADs 
increases cardiac output, decrease pulmonary capillary wedge pressure (42) and 
pulmonary vascular resistance (18, 19), and eventually improve right ventricular 
structure and function. Moreover, LVADs decrease plasma epinephrine, 
norepinephrine, arginine vasopressin, renin and angiotensin II (43) as well as 
circulating and myocardial inflammatory mediators such as interleukin 2 and 
tumor necrosis factor (44). The renal and hepatic dysfunction that is  typical of 
end stage HF, improves as well (45, 46). Six months of LVAD treatment 
essentially normalizes liver enzymes, bilirubin, blood urea nitrogen, and serum 
creatinine in patients who had previous renal and hepatic dysfunction and also 
maintains values in patients who had normal pre-LVAD levels (29, 47). 
Specifically, in patients with HMII, overall LVEF increased from 17% at the time 
of implantation to 25% 6 months later (p < 0.01). LV mass decreased from 114 
g m-2 to 95 g m-2 30 days after LVAD implantation and continued to fall 
progressively over the 1-year follow-up. Interestingly, LVEF improved to >40% in 
a significant proportion (19%) of patients. Most of the improvement in LVEF was 
achieved within 6 months with little if any improvement after this cutoff (48). 
Younger age and shorted duration of HF were the main predictors of recovery. 
Importantly, the patients who recovered LVEF received the same post-VAD 
cardiac medications and had the same incidence of non-ischemic cardiac 
disease as the patients who did not recover LVEF (48). 
Ultimate success of LVAD-associated myocardial recovery implies successful 
explantation of the LVAD followed by sustained normal cardiac function. The 
typical rate of explantation in patients with non-ischemic cardiomyopathy is 
10~20% (49) although there are also some outlying studies that have much 
higher recover rates (50, 51). Since the number of patients qualifying for LVAD 
DT is expanding rapidly, a considerable number of patients could potentially be 
explanted in the next few years. Recovering myocardium should be a goal in 
most LVAD implants, at least in non-ischemic patients. 
Dandel et al. (52) have proposed a protocol to help ensure stable cardiac 
function after the explant, and to minimize the risk of having to re-implant the 
LVAD if the attempt to remove mechanical support fails. They suggest turning the 
LVAD to its minimum speed (6200 revolutions per minute for the HMII) and only 
proceeding with the VAD explantation if LVEF recovers to ≥45%. This test 
predicts cardiac stability that lasts for at least 5 years in 79% of cases. Increasing 
10 A 
Table 1 Outcomes of patients on LVADs (Studies with BTT only are not included. Either mixed DT/BTT or DT only are 
included.) 
 
 
 Setting Patients 
population 
Indication Device Measure 1 
month 
6 
months 
1 year 2 
years 
3 
years 
Actuarial 
survival 
Pulsatile LVADs 
Rose et al., 
2001 (4) 
REMATCH 68 patients DT HMI Survival   52% 29%   
Butler et al., 
2005 (17) 
Multiple 
centers 
222 patients Mixed 
BTT and 
DT 
Novacor Survival 84.1% 57.5% 42.4%    
  1st quartile 
BMI <22.9 
  Survival 81.3% 35% 26%    
  2nd quartile 
BMI 22.9 to 
26.3 
   81.3% 60% 34.9%    
  3rd quartile 
BMI 26.4 to 
29.4 
   92.1% 65% 50%    
  4th quartile 
BMI >29.4 
   81.8% 73% 66%    
10 B 
Butler et al., 
2005 (21) 
Multiple 
centers 
222 patients Mixed 
BTT and 
DT 
Novacor Survival       
  57 patients 
with diabetes 
   76.6% 45.6% 30.4%    
  165 patients 
without 
diabetes 
   86.7% 62.4% 47.1%    
Lietz et al., 
2007 (38) 
 280 DT HMI  86.1%   
  
 56% 30.9%   
 Rogers et 
al., 2007 
(39) 
The INTrEPID 
(Investigation 
of 
Nontransplant-
Eligible 
Patients Who 
Are Inotrope 
Dependent) 
trial 
37 DT Novacor   46% 27%    
Mixed pulsatile and continuous flow LVADs 
Long et al., 
2008 (40) 
Utah Artificial 
Heart Program 
23 DT HMI and 
HMII 
Survival   77% 77%   
10 C 
Daneshmand 
et al., 2010 
(36) 
Duke 
University 
60 patients 
ineligible 
for standard 
list cardiac 
transplantation 
DT HMI and 
HMII 
Survival 93%  78%  50%  
Kirklin et al., 
2012 (35) 
INTERMACS 1287 DT HMI and 
HMII 
   75% 62%   
Randomized trial of pulsatile versus continuous flow LVADs 
Slaughter et 
al., 2009 (6) 
Randomized 
controlled trial 
66 DT HMI Survival 
 
  55% 24%   
     Survival free 
from disabling 
stroke and 
reoperation   
   11%   
  134  HMII Survival   68% 58%   
     Survival 
survival free 
from disabling 
stroke and 
reoperation   
   46%   
Continuous flow LVADs 
Adamson et Single center, 55 Mixed HMII Survival       
10 D 
al., 2011 (11) trials at a 
community 
hospital 
BTT and 
DT 
  30 patients 
aged ≥70 
   97%  75% 70%   
  25 patients 
aged ≤70 
   96%  72% 65%   
Boyle et al., 
2011 (31) 
University of 
Minnesota, 
University of 
Pittsburgh and 
Columbia 
University 
101 patients Mixed 
BTT and 
DT 
HMII or 
VentrAssist   
Actuarial 
survival   from 
the date of 
implant to 
death,  
transplantation, 
LVAD 
explantation, or 
if they 
remained 
LVAD on 
September 1, 
2009 
      
  28 patients 
INTERMACS 
        51.1% 
10 E 
profile 1 
(cardiogenic 
shock) 
  49 patients 
INTERMACS 
profiles 2 or 3 
(inotrope-
dependent 
and 
hospitalized) 
        68.8% 
  24 patients 
INTERMACS 
profiles 4 to 7 
(outpatients 
with low 
functional 
capacity) 
        95.8% 
Brewer et al., 
2012 (16) 
The HMII BTT 
and DT trials 
896 patients Mixed 
BTT and 
DT 
HMII        
  48 
underweight 
     73±7%,  
  
59± 
9% 
  
10 F 
patients 
(BMI<18.5)  
  596 
normal weight 
patients (BMI 
18.5-30)   
     71 ± 
2%, 
60± 
2% 
  
  164 obese 
patients (BMI 
30-35) 
     76 ±4% 66± 
5% 
  
  88 extremely 
obese patients 
(BMI≥35) 
     79 ±5% 68± 
6% 
  
Park et al., 
2012 (34) 
The HMII DT 
trial  
 DT HMII        
  133 patients 
(early cohort) 
     68±4% 58±4%   
  281 patients 
(mid-trial 
cohort) 
     73±3% 63±3%   
 
 
 	  
	  
	  
The VAD Journal: http://dx.doi.org/10.13023/VAD.2014.02   Page 11 of 39 
 
The VAD Journal: The journal of mechanical assisted circulation and heart failure 
the LVEF threshold to ≥50% increases the predictive value of the weaning test to 
92%. 
Table 2. Recovery of left ventricular function as defined by successful 
explantation of the device (from Guglin et al. (53)) 
Study, year Total 
number 
of 
patients 
Number 
(%) of 
recovered 
overall 
Number of 
nonischem-
ic patients   
Number (%) 
of 
nonischem-
ic patients 
recovered 
Outcomes 
Mancini et 
al., 1998 (54)  
111 5 (4.5%) 51 4 (7.8%) 20% survival with 
no recurrence of 
HF at 15 months   
Farrar et al., 
2002 (55) 
 271  22 (8.1%) 271 22 (8.1%) 86% and 77% 
transplantation-free 
survival at 1 year 
and 5 years 
Gorscan et 
al., 2003 (56) 
18  6 (33.3%) 13 5 (38.5%) No HF recurrence 
in 67% at 1 year 
Simon et al., 
2005 (57) 
154 10 (6.4%) 74 8 (11%) 80% alive and free 
from transplant at 
1.6 ± 1.1 years 
Matsumiya et 
al., 2005 (58) 
11 5 (45.5%) 11 5 (45.5%) No HF recurrence 
during follow-up 
ranging 8 to 29 
months 
Dandel et al., 
2005 (49) 
131 32 (24%) 131 32 (24%) 68.8% had no 
recurrence at three 
years 
Birks et al., 
2006 (51) 
15 11 (73.3) 15 (100) 11 (73.3) Long term survival 
91%, rate of 
freedom from 
recurrent HF 
among the 
surviving patients 
100% at 1 year and 
88.9% at 4 years   
Maybaum et 67 6 (9%) 37 5 (13.5%) No death or 
transplants at 6 
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Study, year Total 
number 
of 
patients 
Number 
(%) of 
recovered 
overall 
Number of 
nonischem-
ic patients   
Number (%) 
of 
nonischem-
ic patients 
recovered 
Outcomes 
al., 2007 (59) months 
Dandel et al., 
2008 (60)  
 188 35 (18.5%) 188 35 (18.5%) Transplant-free 
survival 76.2 ± 
8.1% and 70.7 ± 
9.2% at 5 years 
and 10 years  
Birks et al., 
2011 (50) 
19 12 (63.2) 19 (100) 12 (63.2) 83.3% survival 
without HF 
recurrence at 1 and 
3 years 
Lamarche et 
al., 2011 (61) 
17 4 (23.5%)  3 Number of patients 
with ischemic/ 
nonischemic 
cardiomyopathy 
and long-term 
follow-up is not 
reported 
 
Complications 
1. Right ventricular failure  
A downside of LVAD DT is frequent re-admissions related to complications. 
These can occur soon and long after the operation. Right ventricle (RV) failure is 
one of the most important problems. 
Augmenting the failing LV with an LVAD improves hemodynamics immediately in 
patients with isolated LV failure. The situation is more challenging for patients (for 
example, most patients with ischemic cardiomyopathy) who have biventricular 
failure. Since no devices are yet approved for DT for right or bi-ventricular failure, 
the risk of RV failure post-LVAD needs to be assessed before every potential 
implantation. We have recently published a detailed discussion of risk predictors 
and risk scores that are relevant to candidate selection (62). 
Increased blood flow in the postoperative period after LVAD implantation raises 
the workload of the RV. The septum is also shifted to the left which increases the 
RV’s end-diastolic volume and compromises its contractility. If the RV was 
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already compromised before LVAD implantation, it may recover slowly, or not at 
all, after the surgery (48). The most favorable scenario is a gradual reduction of 
RV volume, ventricular mass, diameter of cardiomyocytes, and normalization of 
myocardial collagen content and chamber stiffness (63, 64). 
Specific data obtained from DT HMII patients 1 month after surgery are as 
follows (65).. Central venous pressure decreased from 12.4 ± 5.9 to 8.7 ± 4.5 
mm Hg (p < 0.001). Systemic pulmonary arterial pressure decreased from 52.3 ± 
14.1 to 36.8 ± 11.3 mm Hg (p < 0.001). RV ejection fraction increased from 33.1 
± 4.9% to 40.4 ± 6.2% (p < 0.001). In addition,  RV end diastolic dimension 
decreased, RV stroke work index improved, and  qualitative RV function on 
echocardiography improved from 57.1% moderately or severely reduced pre-
operatively to 38.1% after 1 month (p = 0.008). 
RV failure occurs when a patient exhibits at least two weeks of inotrope 
dependency, or if the patient develops late onset inotrope dependency within two 
weeks of the LVAD implantation, or if they need an RVAD. This happens in 5-
13% of patients after LVAD implantation, and results in prolonged intensive care 
stay, higher mortality, greater risk of bleeding, and more renal insufficiency (66, 
67). 
Measurements that indicate potential postoperative RV failure include: low 
fractional area change and stroke-work index estimated by echocardiologry, high 
central venous pressure (even with normal or near normal pulmonary capillary 
wedge pressure), elevated liver enzymes and creatinine (as signs of congestion), 
and low or normal pulmonary artery systolic pressure. The Berlin group uses the 
RV-to-LV end-diastolic diameter ratio of >0.72 to identify patients with high risk 
for postoperative RV failure (68). 
Several scores have been proposed for calculating the risk of RV failure post 
LVAD. One of them emphasizes requirements for vasopressors, liver function, 
and creatinine (69) while another other score highlights hemodynamic 
parameters (70). Focusing specifically on RV failure after HMII, Kormos et al. 
(71) identified a central venous pressure/pulmonary capillary wedge pressure 
ratio of greater than 0.63, need for preoperative ventilator support, and blood 
urea nitrogen level of greater than 39 mg dL-1 as independent predictors of RV 
failure after LVAD. In practice, despite all of these studies, it remains challenging 
to predict the post-LVAD performance of the RV for an individual patient. 
Deswarte et al. (72) gave dobutamine (maximal dose 15 mcg kg-1 min-1) to 
patients before they received an LVAD. The authors showed that if dobutamine 
increased the tricuspid annular plane systolic excursion by at least 40% and/or 
pulmonary artery systolic pressure by at least 30%, this ruled out post-LVAD RV 
failure with 100% specificity and sensitivity. 
Treatment strategies for post-LVAD RV failure include decreasing RV afterload 
with intravenous vasodilator agents (especially phosphodiesterase-inhibitors 
such as Sildenafil) and increasing contractility with inotropes such as milrinone or 
dobutamine. Milrinone has been show to be the most effective inotrope for 
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reducing pulmonary vascular resistance and increasing LVAD flow (73). Some 
surgeons initiate inhaled nitric oxide in the operating room but this policy often 
requires simultaneous use of vasopressor agents to offset the associated 
vasodilation and resultant hypotension. 
It has also been shown that repairing the tricuspid valve in patients with 
moderate-to-severe or severe tricuspid regurgitation at the time of LVAD implant 
can prevent RV failure in post-operative period (74, 75). 
In general, RV failure that develops early in the postoperative phase can be 
overcome using inotropes and short-term or intermediate-term devices for RV 
mechanical support. RV failure that develops late, or which persists for months 
after LVAD implantation, is more difficult to manage. Sometimes patients are 
discharged on inotropes, or their transplant status is reconsidered, and they are 
put on the waiting list. 
2. Gastrointestinal bleeding  
Managing complications is critical if patients receiving LVAD DT are to maintain a 
good quality of life. Bleeding in general is the most common complication in 
patients on LVADs, with major bleeding observed in about 20% -45% of cases 
(76, 77). Patients on continuous flow support require anticoagulation and have 
transfusion requirements which are double those of patients on pulsatile pumps 
(77). In the HMII DT trial, as many as 81% patients required a blood transfusion, 
and 30% required re-exploration for bleeding (6). 
Gastrointestinal (GI) bleeding in particular is the most serious problem 
associated with LVAD DT. It significantly reduces the quality of life of many 
patients, leading to multiple admissions, unpleasant diagnostic tests, repeated 
blood transfusions, and generally unsatisfactory solutions. 
GI bleeding affects 18 to 40% of patients with LVADs (77-81). Counting only 
episodes requiring transfusions of ≥ 2 units of packed red blood cells  within 24 
hours, Boyle et al. (82) reported GI bleeding in 9.4% of outpatients who were 
supported by a HMII device. These events formed 50% of all recorded bleeding 
incidents and were occurring a rate of 0.23 events/patient-year. 
The proportion of patients who bleed repeatedly is 44% (78). The majority of 
these individuals (60%) bleed from the same site. The distribution of bleeding 
sites is as follows: upper GI tract, 89% (including 54% bleeding from gastric 
erosions, 15% from gastric ulcers, and 15% from angiodysplasias), lower GI 
tract,35% (equally distributed between cecal/rectal ulcers and small bowel 
angiodysplasias) (78). The mean time to bleeding the LVAD implantation was 
128 ±155 days. 
Additional data suggest that 31% of GI tract bleeding events are caused by 
arterio-venous malformations (79). Since malformations in the proximal jejunum 
cannot be detected by routine upper endoscopy and are highly prevalent in 
patients receiving LVAD DT, many centers now perform capsule endoscopy as 
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part of the early evaluation of GI bleeding. Risk factors for GI bleeding include 
advanced age, prior GI bleed, a high international normalized ratio (IRN), and low 
platelets (78). Fortunately, the death rate (even in recurrent GI bleeding) remains 
only 1% (78). 
Aggarwal et al. (78) analyzed echocardiograms and showed that the aortic valve 
opened in 17% of patients who had GI bleeds and 30% of non-bleeders. This 
suggests a potential link between pulsatility and GI bleeding. However the inter-
group difference was not statistically significant, potentially due to the relatively 
small sample size. 
Factors that may contribute to the high incidence of GI bleeds in patients who are 
supported by HMII devices include: 
• Narrow pulse pressure with limited pulsatility. As in the case 
of tight aortic stenosis (Heyde’s syndrome) (83), low pulse 
pressure causes hypoperfusion and hypoxia of the gut, resulting in 
vascular dilatation and angiodysplasia (78) 
• Acquired von Willebrand syndrome. This condition is also 
associated with severe aortic stenosis (84) and is probably caused 
by mechanical depletion of high-molecular-weight von Willebrand 
factor multimeres. Multimeres are lost within days of the LVAD 
implant (85), possibly due to the effects of shear stress on the 
structure of von Willebrand factor (76, 77, 86). 
• Neoangiogenesis. Some fragments of von Willebrand factor may 
be proangiogenic and actually promote angiodysplasia (76, 87). 
• Impaired platelet function. Platelet numbers, function, and 
activation are reduced in patients who are supported with 
continuous flow LVADs (76, 88). 
Unfortunately, none of these factors fully explain why some patients develop 
chronic recurrent GI bleeds and others do not. Many centers have therefore used 
their clinical experience to develop protocols that they follow in the event of GI 
bleeding. One of the typical protocols (78) includes: 
• holding of all anticoagulation and antiplatelets agents. 
• decreasing the VAD speed to create pulsatility 
• administering proton pump inhibitors. 
• administering octreotide (either as a continuous infusion or by 
subcutaneous injection). 
• resuming anticoagulation at a lower INR goal of 1.5-2.0. 
Although it seems physiologically advantageous to have some pulsatility, LVAD 
speed and pulse index are not consistent predictors of GI bleeding. In one study, 
reduced pulsatility index was associated with an increased risk of bleeding 
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(hazard ratio, 0.60; 95% confidence interval, 0.40-0.92; P=0.02) (89), while in 
another study, VAD speed and PI were not significant predictors of GI bleeding 
(78). 
Octreotide is a synthetic somatostatin analogue which inhibits gastric acid 
secretion and reduces portal and splanchnic circulation. There is some evidence 
that it is helpful. Nardone et al. (90) showed that subcutaneous injections for 6 
months produced full or partial control of bleeding in 14 of 17 patients with 
angiodysplasias. On the other hand, Barbara et al. (91) reported no favorable 
effect. Similarly, a study showed that octreotide did not impact the amount of 
packed red blood cells used, rebleeding rates, length of hospital stay, or all-
cause mortality (78). 
There are some anecdotal reports of patients being off all anticoagulants for 
months after a major bleed. However, these practices may raise the incidence of 
pump thrombosis. There is also a report of successful use of danazol, a synthetic 
steroid that has weak androgenic and anti-estrogenic effects (92). 
3. Pump thrombosis  
Pump thrombosis is a serious and potentially fatal complication of LVAD therapy. 
If thrombosis is not treated with a heart transplant or LVAD replacement, the 
mortality approaches 50%. In clinical trials, the rate of thrombosis was low, but 
between 2011 and 2013 several high volume centers documented a sharp rise 
(from 2.2% to 8.4%) of pump thrombosis in the first three months after the 
implantation. The time from implant to pump thrombosis also shortened from 
18.6 to 2.7 months (93). This increase was also apparent in an analysis of 
INTERMACs data (94). 
Preexisting LV thrombi that are dislodged during the surgery can be pulled into 
the LVAD device. This problem becomes less frequent as surgeons gain 
experience. A more important problem is formation of new thrombi after the 
LVAD has been implanted. The heat generated by the LVAD can cause new 
clots to form and grow on the inflow bearing or on the rotor itself (95). 
Prothrombotic conditions can facilitate this process (96). These include: 
significant infection, sub-therapeutic anticoagulation, low flow state, hereditary 
thrombophilias such as protein S, protein C, or factor V Leiden deficiency, and 
antiphospholipid syndrome (95). 
The surgical technique also seems to influence pump thrombosis and 
malposition of the inflow cannula and deformed outflow grafts have been linked 
to post-LVAD clots (97). Decreasing the LVAD flow to facilitate intermittent 
opening of the aortic valve increases the rate of thromboembolic events (98). 
This may be because high flow rates dissipate heat from the LVAD more 
effectively than low flow conditions. Clinically, it is thus important to achieve a 
balance between a high flow rate (which reduces thrombosis) and a low flow rate 
(which increases the incidence of bleeding). 
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Pump thrombosis typically presents with evidence of hemolysis clinically manifest 
as very dark cola colored urine, and a plasma free hemoglobin >30 mg dL-1, 
elevated lactate dehydrogenase, decreased haptoglobin, increased pump power, 
new palpable pulse, new opening of the aortic valve, worsening of mitral 
regurgitation on echocardiography (99), and sometimes symptoms of HF. Data 
suggest that increased lactate dehydrogenase (>600 U/mL for HMII and >400 
U/mL for Heartware) is the most reliable predictor of pump thrombosis (100), and 
some centers have adopted the policy of immediate hospitalization based on 
elevated LDH alone. The best way to treat patients who have elevated LDH but 
no clinical signs of pump thrombosis is still unclear. 
Some cases may be diagnosed with CT angiography (101) but while both 
cannulae can be visualized, the pump itself is not radiolucent. Recently, specially 
designed ramp protocols were suggested as a way to determine the presence of 
thrombi inside the LVAD device (102, 103). In addition to increasing the standard 
antithrombotic and anticoagulation drugs, thrombolytics and IIB/IIIA antagonists 
have been used empirically with intermittent success but multiple complications. 
Frequently, the only realistic option is pump exchange. This procedure is 
relatively safe for HMII devices with postoperative deaths within 30 days of 6.5% 
(104) (Table 3). 
Table 3. Outcomes of pump thrombosis with different therapeutic 
interventions 
Source N LVAD Intervention Outcome 
Thenappan et 
al. (105), 2013 
 
2 HMII Alteplase 
(after heparin 
and 
eptifibatide 
failed) 
Alteplase – 100% 
success 
Eptifibatide 100% 
failure 
No complication 
reported, but long 
term outcome not 
specified 
Al-Quthami et 
al. (106), 2012 
2 HMII Eptifibatide   100% success, GI 
bleed in both   
Tellor et al. 
(107), 2013 
17 
patients, 
total of 22 
attempts 
16 HMII,  
1 
Heartware 
Eptifibatide   3 (17.6%) – 
success 
14 (22.4%) – 
failure, including 7 
(41.2% deaths) 
Complications: 
bleeding 
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11 pts (64.7%) 
including SAH in 2 
Conclusion: 
Risk of using 
eptifibatide 
outweighs the 
proposed benefit of 
salvaging the 
existing LVAD. No 
correlation between 
the dose and the 
outcome. 
Hasin et al. 
(108), 2013 
8 HMII 6 Heparin+ 
clopidogrel   
 
 
1 
Heparin+clopi
dogrel 
+eptifibatide  
 
1 Heparin 
+alteplase   
All survived acute 
episode but had 
recurrent 
hemolysis, stroke in 
1 
(100% failure) 
 
100% success 
(resolved but GI 
bleed with 12 units 
transfused) 
 
100% failure 
   
In 4 pumps which 
were eventually 
explanted, the clot 
was present in all. 
Schlendorf et 
al. (109), 2014 
8 HMII  Alteplase 3 (37.5%) success 
5 death  or 
exchange or 
transplant 
Muthiah et al. 5 Heartware 1 tirofibane  100% success, with 
massive  
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(110), 2013  
1 alteplase 
and 
tenecteplase 
success  
 
1 tenecteplase 
died 
 
1 alteplase 
died 
 
1 alteplase+ 
tirofiban  
 
Clopidogrel 
used in 4 of 5 
 
hemithorax 
 
100% success, with 
epistaxic 
 
 
100% failure 
 
100% failure 
 
100% success but  
transplant in 8 days 
therefore no long 
term f/u 
 
No intracranial 
bleeds 
Aissaoui et al. 
(111), 2012 
7 
episodes 
in 6 
patients  
Heartware 5 pump 
exchanges (1 
after failed 
tenecteplase) 
2 tenecteplase    
Pump exchange 
100% successful 
Tenecteplase 50% 
successful 
Najjar et al. 
(112), 2013   
34 
episodes 
in 31 
patients  
Heartware 30 medical 
therapy   
 
 
 
4 heparin 
 
19 alteplase    
 
15 (50%) success, 
with 5 bleeding 
events, including 2 
hemorrhagic 
strokes. 
15 (50%) failure, 
with 1 death, 2 
urgent transplants, 
12 pump 
exchanges 
No success with 
heparin alone 
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6 epitifibatide 
 
16 pump 
exchanges   
  
 
Alteplase 12 of 19 
(63.2%) success 
 
3 (50%) success  
 
12 (75%) success 
 4(25%) deaths 
 
No statistical 
difference in 
survival at 6 
months between 
those 
patients treated 
medically 
compared to 
patients that 
underwent device 
exchange (91.7% 
vs. 68.8%) 
Starling et al. 
(93), 2014     
38  
 
 
 
19  
HMII Medical 
management, 
no details 
 
Pump 
exchange 
18 (50% success) 
 
 
 
18 (95.5% success) 
Ota et al. 
(113), 2013 
19 with 
pump 
thrombosi
s, out of 
30 total  
HMII Pump 
exchange 
27 (90%) success, 
3 death (10%) for 
the whole cohort, 
without subanalysis 
by the cause  
Pagani et al. 
(114), 2009 
4 HMII  Pump 
exchange   
2 (50%) success, 2 
died   
Stulak et al. 14 with 
pump 
HMII Pump Overall excellent 
results, not 
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(115), 2013 thrombosi
s, out of 
57 total 
episodes  
exchange  stratified by type of 
the device or the 
reason for 
exchange 
Ravichandran 
et al. (116), 
2013 
9 HMII  Pump 
exchange 
3 (33%) success 
Kirklin et al.  
(94), 2014 
383 (all 
pump 
exchange
s due to 
thrombo-
sis) 
HMII Pump 
exchange 
Freedom from 
pump thrombosis,   
97% at 6 months, 
95% at 1 year, and 
92% at 2 years 
 
The survival after 
pump exchange for 
thrombosis was 
56% at two years 
compared to 69% 
(p<.0001) following 
primary implant. 
 
Although pump 
exchange can be 
performed with a 
relatively low 
hospital 
mortality, survival 
during the 
subsequent 6 
months is 
adversely affected 
with each pump 
exchange. 
Moazami et al. 
(104), 2013 
25 
patients 
with 
pump 
thrombosi
HMII Pump 
exchange 
Outcomes are 
provided for all 
pump exchanges, 
not for thrombosis 
only. 
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s out of 
72 
patients 
exchange
d for all 
causes  
77 
exchange 
procedur
es total  
The 30-day 
operative   6.5% (5 
of 77) 
For the 66 patients 
with HMII to HMII 
exchange 
procedures, at 1 
year, mortality was 
30% + transplant 
5%, 65% alive on 
LVAD 
The freedom from 
major device failure 
at 12 months was 
93% ± 2%. 
Badiye et al. 
(117), 214 
4 HMII Argotroban 3(75%) success 
with tamponade 
due to 
hemopericardium, 
subdural 
hematoma, and GI 
bleed 
 
Note that in Table 4, the data reported for pump exchange include only studies 
where the exchange was performed specifically for pump thrombosis. This 
excludes results from Ota et al (113), Moazami et al (104), and Stulak et al (115). 
Data from Kirklin et al (94) were also excluded because the medical strategies 
preceding pump exchanges were not reported. If these data had been included, 
the success rate for pump exchange would have increased substantially. 
Table 4. Outcomes of pump thrombosis grouped by interventions (derived 
from Table 3) 
 Pump 
exchange 
Thrombolytics IIB/IIIA 
antagonists 
N 53 35 33 
Success 40 19 13 
Success, % 75.5 54.3 39.3 
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Stroke 
There are two forms of stoke in LVAD patients, ischemic and hemorrhagic. The 
annual ischemic stroke rate with optimal medical treatment is 5.2% (4). Boyle et 
al. (82) reported ischemic and hemorrhagic stroke rates per patient-year at 4.1% 
and 3.2%, respectively. 
A factor that seems to influence the incidence of stoke is the level of 
anticoagulation. About 40% of ischemic strokes occurred at INR < 1.5, and 33% 
of hemorrhagic strokes occurred at INR > 3.0 (82).  Routine aspirin therapy (81 
mg daily) and maintaining INR in the 1.5 to2.5 range may balance the risks of 
thrombosis and hemorrhage (82). The risk of ischemic stroke is increased if 
mean arterial pressure is above 90 mmHg and if there is a history of stroke. The 
odds almost double in the presence of systemic infection (118). 
Table 5 summarizes the incidence of strokes in LVAD studies. 
Table 5. Hemorrhagic stroke, and ischemic stroke rates in patients with 
HMII implanted for DT or BTT indications (modified from Eckman et al. (76), 
with permission)   
 Hemorrhagic CVA  
per Patient-Year 
Ischemic CVA  per 
Patient-Year 
HMI/HMII (119) 0.05 0.13 
HMII (5) 0.05 0.09 
HMII (6) 0.07 0.06 
HMII(120) 0.01 0.06 
HMII (121)   0.04-0.07 0.04-0.09 
Heartware (122) 0.08 0.05 
HMII (82) 0.032 0.041 
 
Infection 
Drivelines that pass through the patient’s skin to the implanted device are an 
“Achilles heel” of prosthetic pumps because it makes driveline infections a 
permanent threat. In the HMII DT trial, the rate of LVAD-related infections was 
0.90 and 0.50 events/patient-year for HMI and HMII respectively (6). 
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In patients supported primarily by HMII devices for at least a year, infectious 
complications led to 43% of re-admissions and occurred in the driveline (47%), 
blood (37%), and LVAD pocket (20%) (37). In a prospective multicenter study of 
VAD infections, where 57% of patients had HMII devices, 22% of patients 
developed VAD-related infections with an incidence rate of 0.10 per 100 person-
days. The driveline was the most commonly infected site, with Staphylococcus 
being the most common pathogen, followed by Pseudomonas or other Gram-
negative bacteria. Importantly, there was no difference between HMI and HMII, 
but regardless of the device, infection increased one-year mortality (adjusted 
hazard ratio=5.6; P<0.0001) (123). 
In the Mayo clinic cohort, driveline infections were also the most common  (47%), 
followed by bloodstream infections (24% VAD-related, 22% non-VAD related). 
The most common causative pathogens include gram-positive cocci (45%) and 
gram-negative bacilli (27%). Only 42% of the patients were managed by 
antibiotics while others had to undergo surgical procedures. A small number of 
patients had to have their LVAD removed (124). Importantly for DT patients, the 
odds of having a driveline infection increase by 4% for every month of support 
(125). 
Prevention of the infection is achieved by surgical techniques, stabilizing the 
driveline to minimize motion, and meticulous attention to hygiene. Aseptic rules 
should be followed and patients and their caregivers should wear sterile gloves 
and a mask as they clean the exit site daily with antimicrobial soap. After 
cleaning, the site should be rinsed with sterile saline and covered with a sterile 
gauze. 
Aortic Regurgitation 
Aortic regurgitation may create problems in LVAD patients. If regurgitant flow 
persists throughout systole and diastole, this can limit forward flow to the 
periphery. This can compromise end-organ perfusion even when the LVAD flow 
readings are abnormally high (7 to 10 L min-1) (126).  While minimal symptoms 
can be addressed with diuretics and afterload reduction, surgical repair or 
replacement of the aortic valve may be needed in more serious cases (126).  
Because aortic regurgitation tends to worsen over time, some advocate 
prophylactic aortic valve repair at the time of LVAD implant in patients with more 
than trivial aortic regurgitation (126). 
Few patients (~3%) develop more than mild AR after LVAD (65). There are also 
anecdotal reports of percutaneous transcatheter aortic valve closure in VAD 
patients (127). 
Arrhythmias 
The frequency of ventricular tachycardia /fibrillation (VT/VF) has increased 
significantly with the change from pulsatile to continuous flow VADs. VT/VF now 
occurs in about one third of patients who have a continuous flow LVAD (128-
130). This problem is due in part to the new ability to adjust pump speed and 
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instantaneously adjust preload. As a result, the LV chamber size can be reduced 
until the septum touches the VAD drainage cannula. This causes a suction event 
and triggers VT. Reducing the LVAD speed to expand the LV cavity may resolve 
the issue. Other causes of VT/VF include a pre-existing post-MI myocardial scar, 
as well as a new scar which can develop in a small percentage of patients at the 
apical device cannulation site. VT/VF in this case can sometimes be treated 
successfully by catheter ablation (131). 
Because cardiac output in patients who have continuous flow LVADs is not 
dependent on systole and diastole, ventricular arrhythmias are relatively well 
tolerated. A continuous flow LVAD successfully provided hemodynamic support 
to a patient in sustained ventricular fibrillation for over 12 hours (132). The effect 
of automated implanted defibrillators on mortality in LVAD patients is 
controversial. Some data show that the defibrillators still reduce mortality (129) 
but other data show no impact (130, 133). 
Although LVADs protect from hemodynamic compromise in arrhythmias, they 
can initiate symptoms including right heart failure and recurrent syncope. 
Persistent atrial fibrillation may be associated with increased mortality and HF 
hospitalization, as well as with thromboembolism at higher levels of 
anticoagulation (134). In persistent atrial flutter, radiofrequency ablation can 
resolve symptoms (135). 
Non-cardiac Surgery 
As survival rates increase, patients with LVADs are developing additional health 
problems that require treatment. This sometimes includes surgery. Non-cardiac 
surgery in patients on continuous flow devices is a relatively new problem, and 
there are very few studies addressing this issue. 
In one cohort of 36 LVAD patients who underwent 63 non-cardiac surgeries, 30-
day mortality was 16% (136). Most of the surgeries were abdominal but 
urological operations and craniotomies were also performed. None of the 
patients who died were undergoing elective surgeries. All the deaths occurred in 
patients who had to have emergent operations and half of these were 
neurosurgeries for intracranial hemorrhage. Two-thirds of the surgeries did not 
use Swan-Ganz catheters or arterial lines for monitoring. Mean blood pressure 
was maintained above 70 mm Hg. LVAD parameters were monitored and 
adjusted as required either by an LVAD coordinator or perfusionist experienced 
with LVAD management (136).  
In another series, 33 patients with LVADs underwent general anesthesia for 67 
non-cardiac operations (91). Postoperative bleeding was the only complication 
and this occurred in 12 patients. 3 patients died within 30 days of their operation 
for reasons unrelated to the LVAD (91).  A further study by Morgan et al. (137) 
reports no peri-operative deaths, thromboembolic complications, or device 
malfunction in 20 non-cardiac operations. 
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Recommendations for patients on LVAD support undergoing a non-cardiac 
operation include stopping warfarin and aspirin prior to the surgery and resuming 
these drugs two weeks after the procedure. Vancomycin and cefazolin can be 
administered before the surgery for antibiotic prophylaxis and continued for 24 to 
48 hours postoperatively (136). Blood products can be used as needed, including 
fresh frozen plasma and platelets. 
LVAD Maintenance 
Optimal outpatient management is the key to good outcomes in LVAD DT. 
Although each LVAD center develops its own protocols, some principles have 
become universal. The HF cardiologist and the VAD coordinator typically work 
together and meet with the patient at each visit. It is helpful if the cardiothoracic 
surgeon is available if needed. 
Mean arterial pressure should be maintained in the 60 ~ 90 mm Hg range. 
Conventional evidence-based medications for HF (angiotensin inhibitors and 
receptor blockers, β-blockers, and aldosterone antagonists) should be continued 
and increased if appropriate to achieve guideline targets. 
Parameters of LVAD function including speed, power, and pulsatility index are 
measured at each visit. Blood flow is estimated automatically from the power and 
speed parameters. The only device parameter that can be manually adjusted is 
the speed of the LVAD. For HMII devices, this is typically in the 8,600 ~ 9,800 
revolutions per minute range. The pulsatility index is averaged over a defined 
time interval and reflects the flow pulses created by LV contractions. 
A recent paper by Topilsky et al. states that there are three goals for optimal 
LVAD therapy: improved cardiac output, LV unloading and preserved pulsatility 
(138). So-called “ramp” protocols are widely utilized to achieve these aims and 
are normally performed under echocardiography guidance. The following 
parameters are measured initially at baseline and then 3~5 minutes after each 
change of LVAD speed: left ventricular dimension, frequency of the aortic valve 
opening, and position of the interventricular septum. LVAD speed is usually 
incremented in steps that are at least 400 revolutions per minute for HMII devices 
and 60 revolutions per minute for Heartware systems. Once the protocol has 
been completed, the cardiologist choses the single device setting (revolutions per 
minute) that optimizes a middle position of the septum, intermittent valve 
opening, and adequate unloading of the LV. 
Setting the pump speed too low may result in an LV that appears dilated. A 
recent publication suggests two novel parameters that may indicate insufficient 
unloading of the LV. These are a rightward deflection of the atrial septum due to 
high left atrial pressure and a mitral deceleration index (the ratio of deceleration 
time to E-wave velocity) that is less than 2 ms / (cm s-1) (138). 
Setting the pump speed too high can cause suction events where the ventricle 
becomes decompressed and the septum shifts so far to the left that it gets 
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sucked into the inflow cannula of the LVAD. This will reduce the power and 
speed of the LVAD and can also initiate clinical episodes of VT. 
Ramp protocols currently vary between institutions. Uriel et al. (102) have 
recently proposed standardizing the approach and provide a detailed step by 
step description of a protocol that can be used to optimize LVAD settings. They 
also note that pump thrombosis is more likely if the LV end diastolic dimension is 
relatively insensitive to the LVAD speed setting. 
Cost of LVAD DT 
LVAD DT using continuous flow devices is expensive but substantially cheaper 
than support using pulsatile pumps ($193,812 versus $384,260 for initial 
hospitalization, respectively, p < 0.001) (6). Although the cost of the actual 
devices has not changed, the switch from pulsatile LVADs to continuous flow 
devices is associated with a 50% reduction in the cost of implant hospitalization 
over the last decade. 
Taking into account hospital stays, re-hospitalizations, and Medicare payments 
for professional services, the cost of LVAD therapy provides more quality-
adjusted life years (QALY) (1.87 vs. 0.37), and life years (2.42 vs. 0.64), than 
medical therapy. The downside is that the five-year costs of LVAD DT are much 
higher ($360,407 vs. $62,856). The incremental cost-effectiveness ratio of the 
continuous flow LVAD is estimated at $198,184 per QALY and $167,208 per life 
year. This is a 75% reduction in incremental cost-effectiveness ratio from 
$802,700 per QALY in 2004 (139). We conclude that although the cost of LVAD 
therapy remains above the defined level of cost-effectiveness in the USA 
($100,000 / incremental cost-effectiveness ratio) the trajectory is encouraging. 
The most realistic way to reduce future costs is to prevent complications because 
hospital readmissions are very expensive. Shifting the indications for LVAD 
therapy towards “less sick” patients will also save costs because these 
individuals will recover faster and develop fewer complications. 
Conclusions 
LVAD as a destination therapy prolongs life and improves its quality in thousands 
of patients with end stage heart failure. In the future, smaller devices, freedom 
from external driveline, better design and durability may further improve the 
outcomes and make prosthetic pumps a more attractive option for patients with 
less severe disease. Partial hemodynamic support, devices for short term right 
ventricular support, and other innovations can potentially reduce complications of 
current LVADs and result in even wider adoption of mechanical circulatory 
support by both physicians’ community and general public. 
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